Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 11
Submit an article Journal homepage
228
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report

Federica CocitoDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, ItalyCorrespondence[email protected]
,
Silvia MangiacavalliDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
,
Paolo BernasconiDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
,
Anna A. ColomboDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
,
Daniela CalderaDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
,
Claudio S. CartiaDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
,
Maya GanzettiDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
,
Daniela TrolettiDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
,
Mario CazzolaDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
&
Alessandro CorsoDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
 show all
Pages 2770-2771 | Received 22 Nov 2016, Accepted 18 Feb 2017, Published online: 13 Mar 2017

References

  • Vigorito AC, Campregher PV, Storer BE, National Institutes of Health, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114:702–708.
  • Baird K, Steinberg SM, Grkovic L, et al. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant. 2013;19:632–639.
  • Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–615.
  • Mohty M, Brissot E, Savani BN, et al. Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant. 2013;19:1416–1420.
  • Finn PW, Stone JR, Boothby MR, et al. Inhibition of NF-kappaB dependent T cell activation abrogates acute allograft rejection. J Immunol. 2001;167:5994–6001.
  • Vodanovic-Jankovic S, Hari P, Jacobs P, et al. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood. 2006;107:827–834.
  • Mateos-Mazon J, Perez-Simon JA, Lopez O, et al. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica. 2007;92:1295–1296.
  • Wang XC, Jobin C, Allen JB, et al. Suppression of NF-kappaB-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor. Invest Ophthalmol Vis Sci. 1999;40:477–486.
  • El-Cheikh J, Michallet M, Nagler A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008;93:455–458.
  • Todisco E, Sarina B, Castagna L, et al. Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib. Leuk Lymphoma. 2007;48:1015–1018.
  • Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.
  • Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389–401.
  • Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947–959.
  • Pai CC, Chen M, Mirsoian A, et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood. 2014;124:1677–1688.
  • Herrera AF, Kim HT, Bindra B, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1737–1743.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.